BioAge Labs Inc. cash flow to debt ratio of -1.47K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

BioAge Labs Inc.'s free cash flow has decreased 58.70% from $-51.89M last year to $-82.35M, signaling decreasing performance

BioAge Labs Inc.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability.

BioAge Labs Inc.'s debt has decreased relative to shareholder equity from 0.03 last year to 0.01 today, signaling strengthened financials

BioAge Labs Inc. has a net cash position, so leverage is healthy.

BioAge Labs Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

BioAge Labs Inc. has insufficient data to evaluate this check.

BioAge Labs Inc.'s short-term assets of $286.79M exceed its short-term liabilities of $20.14M

BioAge Labs Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

BioAge Labs Inc.'s return on equity of -28.99%, is lower than 15.00%, indicating bad performance

BioAge Labs Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

BioAge Labs Inc. has insufficient public price history to evaluate earnings stability.

BioAge Labs Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

BioAge Labs Inc. has negative free cash flow, indicating cash burn

BioAge Labs Inc.'s yearly earnings has decreased 13.35% since last year from $-71.11M to $-80.61M, signaling decreasing performance

BioAge Labs Inc.'s yearly revenue has increased % since last year from $0.00 to $8.99M, signaling increasing performance

ROIC -28.08% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

BioAge Labs Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

BioAge Labs Inc. has insufficient public price history to evaluate revenue consistency.

BioAge Labs Inc. has insufficient public price history to evaluate ROE consistency.

BioAge Labs Inc. has insufficient data to evaluate this check.

BioAge Labs Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

BioAge Labs Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

BioAge Labs Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

BioAge Labs Inc. has insufficient data to evaluate this check.

BioAge Labs Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

BioAge Labs Inc. has a price-to-book ratio of 1.37x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

BioAge Labs Inc. has a price-to-sales ratio of 49.59x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue